Vertiv's only Sell rating, at $188, comes down to a $3.65 billion revenue line
GLJ Research broke ranks on Vertiv with a Sell and a $188 target, built on a 2027 EBITDA estimate below consensus. The referee is management's own guide: third-quarter net sales of $3.65 billion to $3.85 billion, and the floor is the line.
Vincent Jiang · 3 min read
The lone Sell on a quiet tape
Vertiv−1.09% — Vertiv, down 1.09 percent today fell 3.5% on October 7 after GLJ Research's Gordon Johnson initiated coverage at Sell with a $188 target, resting on a 2027 adjusted EBITDA estimate that sits below consensus 1. The shares recovered to $244.73 by the close, still down 3.3%, still up 39.4% for the year and 35% below the May high of $376.23 1.
It is the only Sell among 20 analyst ratings logged in the past three months, against 18 buys, one hold and an average target of $326 3. That $188 sits roughly 23% below the $244.73 close: the distance between GLJ's 2027 EBITDA path and the 56.2 times earnings the market pays for Vertiv, against 21.5 for the index 2.
18 of Vertiv's 20 ratings in the past three months are buys
- Buy1890%
- Hold15%
- Sell15%
Data
| Slice | Value | Share |
|---|---|---|
| Buy | 18 | 90% |
| Hold | 1 | 5% |
| Sell | 1 | 5% |
The de-rate came before the number
The slide started long before the note: down 20% over three months while the S&P 500 gained about 4%, with no financial results since July 29 2. The macro leg is real. The 10-year Treasury yield hit 5.14% in late September, a level last seen in 2007, and Vertiv fell 2.6% that day 1. Eaton lost 3.09%, Emerson 1.35% and nVent 3.44% in the same October 7 session, a power-chain slide rather than a Vertiv story 2.
The power chain slid together on October 7
Data
| Value | |
|---|---|
| Vertiv | -3.5% |
| Eaton | -3.09% |
| nVent | -3.44% |
| Emerson | -1.35% |
GLJ put a price on a move already underway, and on a crowded long: the stock returned 252% in 2023, beating every company in the S&P 500, and only joined the index in March 2026 7. The freshest calls still run the other way: BMO initiated at Buy on October 5, Vertical Research on September 29, Wells Fargo on September 25 3.
The record is real, and the customers pay ahead
The July filing shows the machine working. Q2 net sales were $3,274 million, up 24%, operating profit rose 44%, and trailing revenue reached $11.5 billion against $9.1 billion a year earlier, with operating margin roughly doubled from three years ago 42.
The tell is who pays ahead: deferred revenue, cash banked before delivery, doubled to $3,634 million by mid-year, and the quarter closed in a net cash position 4. The long owns the compounding; the Q3 guide is what has to keep it compounding.
Revenue is up year over year for ten straight quarters; the Q3 guide draws the line at $3.65B
- Net sales
- Estimate
Data
| Net sales | |
|---|---|
| Q1 '24 | $1.64B |
| Q2 '24 | $1.95B |
| Q3 '24 | $2.07B |
| Q4 '24 | $2.35B |
| Q1 '25 | $2.04B |
| Q2 '25 | $2.64B |
| Q3 '25 | $2.68B |
| Q4 '25 | $2.88B |
| Q1 '26 | $2.65B |
| Q2 '26 | $3.27B |
| Q3 '26 guide (estimate) | $3.65B ($3.65–3.85B) |
Below $3.65 billion, minor becomes a verdict
The July release itself called the Q2 wobble "minor timing shifts", citing temporary supply chain congestion and multi-phased project execution, and guided Q3 net sales to $3,650 million to $3,850 million, implying 34% to 36% organic growth 4. EMEA organics fell 2.4% in the quarter, and management expects growth there to return in the second half 42.
Consensus sits at $3.75 billion, and the Street's low estimate, $3.59 billion, already lies beneath the company's own floor 3. William Blair called the volatility transitory on July 30; Bernstein reiterated a $368 buy on the day of the drop 3. Last year's Q3 landed on October 22, and this year's date is not yet posted 6.
Below $3.65 billion, the word "minor" stops being an explanation and becomes a verdict.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
